J
J. W. Van Werkum
Publications - 28
Citations - 970
J. W. Van Werkum is an academic researcher. The author has contributed to research in topics: Clopidogrel & Percutaneous coronary intervention. The author has an hindex of 17, co-authored 28 publications receiving 916 citations.
Papers
More filters
Journal ArticleDOI
A head-to-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention.
J. W. Van Werkum,C. A. K. Van Der Stelt,Toine H. Seesing,Christian M. Hackeng,J. M. ten Berg +4 more
TL;DR: The platelet response to clopidogrel (and aspirin) in 211 consecutive patients undergoing elective PCI with stenting was prospectively studied and absolute P2Y12 Reaction Units (PRUs) were preferred over reported BASE values of the VerifyNow P2y12 assay in the present study.
Journal ArticleDOI
Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel
Heleen J. Bouman,Emel Parlak,J. W. Van Werkum,Nicoline J. Breet,H. ten Cate,Christian M. Hackeng,J. M. ten Berg,Dirk Taubert +7 more
TL;DR: The flow cytometric VASP‐assay, the VerifyNow P2Y12 assay and, although to a lesser extent, 20 μmol L−1 adenosine diphosphate‐induced light transmittance aggregometry (LTA) correlate best with the maximal plasma level of the AMC, suggesting these may be the preferred platelet function tests for monitoring the responsiveness to clopidogrel.
Journal ArticleDOI
The use of the VerifyNow system to monitor antiplatelet therapy: A review of the current evidence
J. W. Van Werkum,Ankie M. Harmsze,Ellen H.A.M. Elsenberg,Heleen J. Bouman,J. M. ten Berg,Christian M. Hackeng +5 more
TL;DR: Insight is given into the principal mechanisms of the VerifyNow system, its clinical utility for the monitoring of antiplatelet therapy and the proposed cut-off levels to segregate responders from non-responders for the different types of anti platelet therapy.
Journal ArticleDOI
High on-aspirin platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events.
Nicoline J. Breet,J. W. Van Werkum,Heleen J. Bouman,Johannes C. Kelder,J. M. ten Berg,Christian M. Hackeng +5 more
TL;DR: AA‐induced LTA and the verifyNow® ASA test were able to identify aspirin‐treated patients undergoing PCI with stenting at risk for atherothrombotic events and the VerifyNow® Aspirin Assay had the highest predictive accuracy.
Journal ArticleDOI
Effect of gender difference on platelet reactivity
Nicoline J. Breet,M. A. Sluman,M. A. J. P. J. van Berkel,J. W. Van Werkum,Heleen J. Bouman,Ankie M. Harmsze,Johannes C. Kelder,Freek J. Zijlstra,Christian M. Hackeng,J. M. ten Berg +9 more
TL;DR: Although the magnitude of platelet reactivity was higher in women, the absolute difference between genders was small and both the cut-off value to identify patients at risk and the incidence of the composite endpoint were similar between genders.